Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is one of the 10 Best Under-the-Radar Stocks to Invest In.
On June 11, BofA lowered its price target on Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) to $542 from $550. It maintained a Neutral rating on the stock. The firm said Rezdiffra’s launch in MASH has impressed, but debate has shifted to whether that momentum can continue. The analyst reduced the firm’s 2028 Rezdiffra revenue forecast to $2.6 billion from $2.7 billion after discussions with key opinion leaders and prior management feedback.
Separately, on July 1, Ribo and Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) achieved the first candidate drug nomination milestone under their siRNA collaboration for MASH. Ribo said the partnership consists of multiple preclinical assets targeting liver diseases.
Li Ming Gan, Ribo’s co-CEO and Global R&D President, said the companies reached the milestone within months. It combined Madrigal’s clinical expertise in MASH with Ribo’s siRNA discovery and delivery capabilities. Both partners plan to speed up development of the novel therapy.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a biopharmaceutical company. It delivers novel therapeutics for metabolic dysfunction-associated steatohepatitis in the United States.
While we acknowledge the potential of MDGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
